Small Cell Lung CancerNCT04451460
Effect of Hyponatremia in Small Cell Lung Cancer
An observational study of Small Cell Lung Cancer, run by Ankara City Hospital Bilkent.
Trial summary
In this retrospective study, the investigators determined the frequency of hyponatremia in small cell lung cancer and the prognosis. 126 (27%) of 466 patients were hyponatremic. Hyponatremia could not be corrected in 50.8% (n=64) of hyponatremic patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Small Cell Lung Cancer
- How many people
- 466 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2012to 1 Jan 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with SCLC between January 2012 and January 2017 in our hospital were retrospectively screened
Who may be able to join
- Patients diagnosed with SCLC between January 2012 and January 2017 in our hospital were retrospectively screened
Who cannot join
- Over 18 age If data doesn't exist
About this study
Official title: Frequency and Effect on the Prognosis of Hyponatremia During the diagnosıs in Small Cell Lung Cancer
In this retrospective study, the investigators determined the frequency of hyponatremia in small cell lung cancer and the prognosis. 126 (27%) of 466 patients were hyponatremic. Hyponatremia could not be corrected in 50.8% (n=64) of hyponatremic patients. Survival was found to be better in the group of whom hyponatremia was corrected.
- Conditions
- Small Cell Lung Cancer
- Keywords
- Small cell lung cancer, hyponatremia, prognosis, treatment, biochemistry
- Medical subject headings
- Small Cell Lung Carcinoma, Hyponatremia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Hyponatremia | Hyponatremic small cell cancer patients | |
| Normonatremia | Normonatremic small cell cancer patients |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
Effect of hyponatremia according to mortality
Measured: Through study completion, an average of 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2020
- Study start1 Jan 2012
- Primary completion1 Jan 2017
- Study completion1 Jan 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by Ankara City Hospital BilkentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 466 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ankara City Hospital Bilkent
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04451460
- Sponsor's protocol ID
- AnkaraSanatoryum
- Status last verified
- Jun 2020
- First submitted
- 1 Jun 2020
- Last updated
- 30 Jun 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Frequency and Effect on the Prognosis of Hyponatremia During the diagnosıs in Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT04451460
- Acronym / sponsor ID
- AnkaraSanatoryum
- Conditions
- Small Cell Lung Cancer
- Keywords
- Small cell lung cancer, hyponatremia, prognosis, treatment, biochemistry
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 466 participants (actual)
- Lead sponsor
- Ankara City Hospital BilkentUniversity, hospital or other
- Study start
- 1 Jan 2012 (actual)
- Primary completion
- 1 Jan 2017 (actual)
- Study completion
- 1 Jan 2017 (actual)
- First posted
- 30 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this retrospective study, the investigators determined the frequency of hyponatremia in small cell lung cancer and the prognosis. 126 (27%) of 466 patients were hyponatremic. Hyponatremia could not be corrected in 50.8% (n=64) of hyponatremic patients. Survival was found to be better in the group of whom hyponatremia was corrected.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hyponatremia | – | –Hyponatremic small cell cancer patients |
| Normonatremia | – | –Normonatremic small cell cancer patients |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with SCLC between January 2012 and January 2017 in our hospital were retrospectively screened
Key inclusion criteria (1 listed)
- Patients diagnosed with SCLC between January 2012 and January 2017 in our hospital were retrospectively screened
Key exclusion criteria (1 listed)
- Over 18 age If data doesn't exist
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mortality
Time frame: Through study completion, an average of 3 months
Effect of hyponatremia according to mortality
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2020.
Related trials for Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Small Cell Lung Cancer, run by Ankara City Hospital Bilkent.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: Through study completion, an average of 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2020; AzTrials last refreshed its copy on 7 Nov 2026.